Research and Development Tax Incentive

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Retrieved on: 
Monday, October 30, 2023

MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023 (Q1 FY24).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2023 (Q1 FY24).
  • In addition, an independent Data Monitoring Committee (DMC) recommended that the trial continue as planned and they expressed no concerns about safety.
  • Today, Alterity announced that screening has closed for its ATH434-201 Phase 2 clinical trial, an important step to completing enrollment in the study.
  • 3938364 covers more than 150 novel pharmaceutical compositions that are designed to redistribute the excess iron implicated in neurodegenerative diseases.

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

Retrieved on: 
Tuesday, August 15, 2023

MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme.

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme.
  • The cash refund relates to the cost of eligible research and development activities conducted during the financial year ended 30 June 2022, and represents the amount disclosed in the company’s audited financial statements.
  • These funds will be used to further Alterity’s clinical development and research activities, including the ongoing Phase 2 clinical trials for the Company’s lead drug candidate ATH434 in Multiple System Atrophy (MSA), a Parkinsonian disorder with no approved therapy.

Licenses for the Smart Contract Platform, Coin Exchange, NFT Exchange, and Smart Contract Exchange become available at UnitedMarket.io

Retrieved on: 
Wednesday, July 5, 2023

Indeed, to this day the legal framework of the Crypto market has not been authoritatively established and this has hurt many companies in the space.

Key Points: 
  • Indeed, to this day the legal framework of the Crypto market has not been authoritatively established and this has hurt many companies in the space.
  • Being unable to attract public funding is one such disadvantage compared to regulated markets.
  • "These systems and methods include Smart Contract platform, Crypto Coin exchange, NFT exchange, and a new type of marketplace - the Smart Contract exchange."
  • Free licenses are available for government and non-profit organizations and startups.

ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

Retrieved on: 
Wednesday, May 24, 2023

The Series A Shares are convertible, and upon conversion, shall at all times be paid with Ordinary Shares and not in cash.

Key Points: 
  • The Series A Shares are convertible, and upon conversion, shall at all times be paid with Ordinary Shares and not in cash.
  • Such listing will be either by IPO, backdoor (shell merger) or direct listing or another mutually agreed method.
  • The Cantheon investment will be exempt from registration under the applicable U.S. federal and state securities laws, rules and regulations.
  • “This financing is a crucial next step in the restructuring of RespireRx and the founding and funding of ResolutionRx.

Ryan Hires Jason Dunnachie as Principal and Practice Leader of Research and Development in Australia

Retrieved on: 
Wednesday, April 26, 2023

Ryan , a leading global tax services and software provider, has announced that Jason Dunnachie has joined the Firm as a Principal and Practice Leader of the Research and Development (R&D) practice in Australia.

Key Points: 
  • Ryan , a leading global tax services and software provider, has announced that Jason Dunnachie has joined the Firm as a Principal and Practice Leader of the Research and Development (R&D) practice in Australia.
  • Based in Sydney, he will work with clients across Australia, Asia-Pacific, and worldwide.
  • “Jason is a prominent leader in the Research and Development sector in the Asia-Pacific region,” said Jon Sweet, Ryan President of European and Asia-Pacific Operations .
  • “I am excited to have joined a firm with a true global outlook,” said Dunnachie.

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

Retrieved on: 
Tuesday, March 21, 2023

Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

Key Points: 
  • Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.
  • Enveric’s lead drug candidate, EB-373, is a next-generation synthetic New Chemical Entity (NCE) designed as a psilocin prodrug and developed leveraging its Psybrary™ drug discovery platform.
  • Enveric expects to initiate a Phase 1 first-in-human clinical trial investigating EB-373 targeting anxiety disorders in the fourth quarter of 2023.
  • “Given this, we are eager to initiate our clinical development program of EB-373 in Australia and look forward to benefiting from the country’s high-quality clinical research sites.”

ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd

Retrieved on: 
Wednesday, March 1, 2023

Collectively, ResolutionRx and RespireRx are leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling.

Key Points: 
  • Collectively, ResolutionRx and RespireRx are leaders in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling.
  • iNGENu is a bespoke contract research organization focused on cannabinoid and psychedelic clinical research.
  • Entry into the Services Agreement with iNGENu.
  • Early preparation for a ResolutionRx initial public offering in Australia, and possibly other international markets at an appropriate future date.

ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits

Retrieved on: 
Wednesday, February 1, 2023

The LOI and Term Sheet summarize the background and principal terms of a series of planned financing arrangements between Radium Capital (“Radium”) and ResolutionRx Ltd, in order to unlock research and development tax credits available in Australia to companies like ResolutionRx.

Key Points: 
  • The LOI and Term Sheet summarize the background and principal terms of a series of planned financing arrangements between Radium Capital (“Radium”) and ResolutionRx Ltd, in order to unlock research and development tax credits available in Australia to companies like ResolutionRx.
  • Radium sponsors a program called Radium Advance to enable businesses to unlock their tax refunds sooner.
  • The annual interest rate on the loans as of February 23, 2023 for new clients is 16%.
  • The loans are repaid by assigning the refund to directly to Radium.

Proactive news headlines including Artrya Ltd, Horizon Minerals, International Graphite and Riversgold Ltd

Retrieved on: 
Thursday, October 27, 2022

Click here

Key Points: 
  • Click here
    Horizon Minerals Ltd (ASX:HRZ) has boosted the funds raised in its share purchase plan (SPP) to $668,391 after closing a shortfall offer.
  • Click here
    Animoca Brands Corporation Ltds subsidiary Grease Monkey Games has dropped its first-ever Nissan utility NFTs for motorsport game Torque Drift 2.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

AdvanCell Closes A$18M Series B Funding Led by Morningside

Retrieved on: 
Wednesday, August 24, 2022

AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.

Key Points: 
  • AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
  • AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options.
  • AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board.
  • For more information visit www.advancell.com.au
    Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm.